In this episode, we talk with Dr. Ji Soo Kim about a new tool designed to help people with scleroderma better understand and manage their disease. Using information collected over many years from patients receiving routine care, Dr. Kim developed an interactive platform that turns complex medical data into easy-to-understand charts and predictions. We discuss how the tool can help patients and doctors track disease progression, compare experiences with similar patients, and make more informed treatment decisions together. Dr. Kim also shares insights into the challenges of working with real-world health data, the future of personalized medicine in rheumatology, and the career path that led to this innovative work.

Development of a Personalized Visualization and Analysis Tool to Improve Clinical Care in Complex Multisystem Diseases With Application to Scleroderma

In this episode, we speak with Dr. Swati Mehta and Dr. Lee Schulman Shapiro about their study examining early- and late-onset scleroderma renal crisis using data from three patient cohorts. They discuss key clinical findings, including important differences related to sex, autoantibodies, presentation, dialysis outcomes, and long-term prognosis, as well as the implications for patient care. The conversation also explores the personal journeys of both guests—from Dr. Mehta's path from northern India to a career at the intersection of nephrology and rheumatology, to Dr. Shapiro's reflections on nearly five decades in clinical practice and life after retirement.

In this episode, we speak with Dr. Nirali Shah about the growing role of artificial intelligence in healthcare and rehabilitation. Drawing from her recent scoping review, Dr. Shah discusses the evidence behind AI-driven health apps for education, exercise, gait retraining, clinical decision support, remote patient monitoring, and pain management. The conversation also explores the challenges, risks, and ethical considerations surrounding AI in clinical care, as well as the future relationship between digital health tools and healthcare professionals.

In this episode, we explore the emerging role of biomarkers in rheumatoid arthritis–associated interstitial lung disease (RA-ILD) with Dr. Brent Luedders, discussing how prior ILD research laid the foundation for his latest multi-cohort study. He walks us through the study design, including the use of VA and non-VA cohorts, the biomarker panel that was tested, and the key findings related to prevalent and incident RA-ILD, ROC analyses, and disease risk over time. We also discuss the study's limitations, the future of biomarkers in RA-ILD care, and Dr. Luedders' personal journey into rheumatology, research, and medical education.

Performance of an Idiopathic Pulmonary Fibrosis-Derived Multibiomarker Panel for Rheumatoid Arthritis-Associated Interstitial Lung Disease

In this episode, Drs. Nilasha Ghosh and Anne Bass discuss immune-related adverse events from immune checkpoint inhibitors, focusing on psoriasis and psoriatic arthritis. They review early clinical recognition, epidemiology, and findings from a multicenter observational study evaluating apremilast, including patient characteristics, outcomes, and key limitations. The conversation also highlights insights from the HSS Checkpoint Inhibitor–Associated Arthritis Registry, the need for greater precision in rheumatology, and practical perspectives on mentorship and career development for emerging clinician–scientists.

Use of Apremilast for the Treatment of Immune Checkpoint Inhibitor Psoriasis and Psoriatic Arthritis

In this episode, Dr. Katie McMenamin and Dr. Josh Baker discuss their research on the genetic drivers of pain in rheumatoid arthritis, drawing on data from the FORWARD and VARA cohorts. They explore how genetic risk scores relate to pain and disease activity, and what these findings mean for patient care, remission, and future clinical trials. The conversation also highlights key study limitations, along with reflections on the research process and advice for trainees pursuing careers in rheumatology.

Development and External Validation of a Genetic Risk Score for Pain in Rheumatoid Arthritis

In this episode, Dr. Shervin Assassi discusses a secondary analysis of the SENSCIS trial, exploring how peripheral blood gene expression may predict response to mycophenolate in systemic sclerosis–associated lung disease. He highlights key findings linking immune and metabolic gene signatures, as well as C-reactive protein, to changes in lung function, and considers their potential role in guiding treatment and clinical trial design. The episode also touches on his career journey and insights into leadership, mentorship, and sustaining research productivity.

Peripheral Blood Gene Expression Profiling and Prognostic Significance for the Course of Interstitial Lung Disease in Patients With Systemic Sclerosis

In this episode, we speak with Dr. Sasha Bernatsky about her research on the relationship between exposure to fine particulate air pollution and the development of systemic autoimmune rheumatic diseases. She explains what fine particulate matter is, how her team used large population datasets to study environmental exposures, and what their findings suggest about the potential health impacts of air pollution. The conversation also explores the challenges and limitations of studying environmental risk factors, what comes next for this line of research, and Dr. Bernatsky's reflections on building a career in rheumatology and epidemiology, mentoring the next generation of scientists, and staying resilient through the inevitable setbacks of scientific work.

Systemic Autoimmune Rheumatic Disease Risk: Association With Long-Term Exposure to Fine Particulate Matter